相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Medical Horizons S.r.l. has secured an exclusive distribution agreement with Canadian company Bowhead Health Inc. to bring AI-powered clinical trial matching technology to Italy, Turkey, and Cyprus. - Bowhead Health's platform addresses the inefficiencies of manual clinical trial matching by enabling hospitals to instantly scan global and local trial databases, particularly capturing genomic details that are often missed. - The AI-driven technology aims to reduce time spent on manual searches while accelerating progress toward personalized medicine by connecting patients with appropriate therapies more efficiently.
- RadNet Inc. has announced plans to acquire iCAD Inc. for approximately $100 million, uniting two leading companies in AI-powered cancer detection technology with a focus on breast cancer screening. - The acquisition, unanimously approved by both companies' boards, is expected to close by Q3 2025 and aims to accelerate innovation in early cancer detection, improve radiologist workflow, and enhance patient outcomes. - The combined entity will leverage RadNet's scale and clinical leadership with iCAD's AI solutions in breast cancer detection, risk evaluation, and density assessment to create a comprehensive platform for advancing population health initiatives.
- iCAD and Koios Medical announce strategic partnership to integrate ProFound AI Breast Health Suite with Koios SmartUltrasound, creating a comprehensive AI-powered breast cancer detection solution. - The collaboration addresses the growing need for advanced diagnostic tools, particularly benefiting women with dense breast tissue who require alternatives to traditional mammography. - The integrated platform aims to enhance workflow efficiency and diagnostic accuracy by providing radiologists with AI-powered capabilities across both mammography and ultrasound modalities.
- iCad's ProFound Detection version 4.0, an AI-powered solution for digital breast tomosynthesis (DBT), has received FDA clearance, marking a significant advancement in cancer detection technology. - The new version demonstrates a 22% overall improvement in detecting challenging cancer subtypes, including a 50% improvement in identifying cancers within dense breast tissue, enhancing early detection. - ProFound Detection version 4.0 offers more precise lesion marking with an 18% overall improvement in cases with no marks, reducing false positives and providing clinicians with a more efficient AI concurrent-reader solution. - iCad expects to expand the availability of ProFound Detection version 4.0 globally and to vendor-specific platforms in 2025, further solidifying its competitive position in cancer detection.
- iCAD's ProFound Detection Version 4.0, an AI-powered solution for digital breast tomosynthesis, has received FDA clearance, enhancing cancer detection and specificity. - The new version demonstrates a 6.3% improvement in AUC, leading to better identification of aggressive cancers and a reduction in false positives. - ProFound Detection 4.0 offers a 22% overall improvement in detecting challenging cancer subtypes, including a 50% improvement in dense breast tissue. - Clinicians can now incorporate prior exams into the AI analysis, improving clinical accuracy and streamlining workflows for more informed decision-making.
